The cardiovascular actions of omapatrilat in spontaneously hypertensive rats

被引：5

作者：

Dong Y. ^{[1
]}

Zhou H. ^{[1
]}

Shaffer E. ^{[1
]}

Atamas N. ^{[1
]}

Liao W.-C. ^{[1
]}

Wei C. ^{[1
]}

机构：

[1] University of Maryland, School of Medicine, 434 MSTF, Baltimore, MD 21201

来源：

Current Hypertension Reports | 2001年 / 3卷 / Suppl 2期

基金：

美国国家卫生研究院;

关键词：

Left Ventricular Mass; Vehicle Group; Fosinopril; Mean Blood Pressure; Neutral Endopeptidase;

D O I：

10.1007/s11906-001-0100-0

中图分类号：

学科分类号：

摘要：

Omapatrilat is a newly developed vasopeptidase inhibitor that inhibits both angiotensin-converting enzyme (ACE) and neutral endopeptidase and has potent antihypertensive efficacy. However, the specific effect of omapatrilat on cardiac function and left ventricular hypertrophy with hypertension remains controversial. Therefore, we investigated the effect of omapatrilat on blood pressure, cardiac hypertrophy, and cardiac function in spontaneously hypertensive rats (SHR). Studies were performed in SHR that received vehicle (n = 9), omapatrilat (n = 10), or fosinopril (ACE inhibitor, n = 7) by daily gavage for 56 days. Systolic blood pressure (SBP) and mean blood pressure (MBP) were measured by tail plethysmography. Left ventricular fractional shortening and left ventricular mass were measured by echocardiography at day 56. Omapatrilat and fosinopril significantly decreased SBP and MBP from day 1 through day 56, and omapatrilat markedly reduced SBP and MBP compared with fosinopril from day 21 to day 56. Although both omapatrilat and fosinopril decreased left ventricular mass and left ventricular mass-tobody weight ratio with increased LV fractional shortening, omapatrilat had a more potent effect on the reduction of left ventricular mass and improvement of cardiac function. This study shows that in SHR, omapatrilat mediated a potent and stable antihypertensive effect and a reduction in left ventricular mass with improvement of cardiac function, compared with ACE inhibition alone. Copyright © 2001 by Current Science Inc.

引用

页码：s1 / s5

页数：4

共 18 条

[1]

Packer M., Drugs for heart failure that interfere with the renin-angiotensin system, Heart Failure: Scientific Principles and Clinical Practice, pp. 687-690, (1997)

[2]

The sixth report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (JNC VI), Arch Intern Med, 157, pp. 2413-2446, (1997)

[3]

Robl J.A., Trippodo N.C., Petrillo E.W., Neutral endopeptidase inhibitors and combined inhibitors of neutral endopeptidase and angiotensin-converting enzyme, Antihypertensive Drugs, pp. 113-211, (1997)

[4]

Richards A.M., Wittert G.A., Crozier I.G., Espiner E.A., Yandle T.G., Ikram H., Frampton C., Chronic inhibition of endopeptidase 24.11 in essential hypertension: Evidence for enhanced atrial natriuretic peptide and angiotensin II, Journal of Hypertension, 11, 4, pp. 407-416, (1993)

[5]

Burnett Jr. J.C., Vasopeptidase inhibition: A new concept in blood pressure management, J Hypertens, 17, (1999)

[6]

Weber M., Emerging treatments for hypertension: Potential role for vasopeptidase inhibition, Am J Hypertens, 12, (1999)

[7]

Trippodo N.C., Robl J.A., Asaad M.M., Fox M., Panchal B.C., Schaeffer T.R., Effects of omapatrilat in low, normal, and high renin experimental hypertension, American Journal of Hypertension, 11, 3, pp. 363-372, (1998)

[8]

Thomas C.V., McDaniel G.M., Holzgrefe H.H., Mukherjee R., Hird R.B., Walker J.D., Hebbar L., Powell J.R., Spinale F.G., Chronic dual inhibition of angiotensin-converting enzyme and neutral endopeptidase during the development of left ventricular dysfunction in dogs, Journal of Cardiovascular Pharmacology, 32, 6, pp. 902-912, (1998)

[9]

Bunag R.D., Butterfield J., Tail-cuff blood pressure measurement without external preheating in awake rats, Hypertension, 4, 6, pp. 898-903, (1982)

[10]

Shorofsky S.R., Aggarwal R., Corretti M., Baffa J.M., Strum J.M., Al-Seikhan B.A., Kobayashi Y.M., Jones L.R., Wier W.G., Balke C.W., Cellular mechanisms of altered contractility in the hypertrophied heart: Big hearts, big sparks, Circulation Research, 84, 4, pp. 424-434, (1999)

← 1 2 →